New Findings in Prostate Cancer Described from Medical University of Vienna (Response To [<superscript>177</superscript>lu]Lu-psma Radioligand Therapy In Metastatic Castration-resistant Prostate Cancer Patients Presenting With Only Lymph Node Metastases).
In: Cancer Weekly, 2024-01-02, S. 639-639
serialPeriodical
Zugriff:
A study conducted at the Medical University of Vienna in Austria examined the effectiveness of [Lu-177]Lu-PSMA radioligand therapy (PSMA-RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC) who only had lymph node metastases. The study found that out of 10 patients analyzed, nine responded well to the therapy, with a significant decline in prostate-specific antigen (PSA) levels. Further courses of PSMA-RLT also resulted in favorable outcomes, including partial remission of the disease. The study concluded that mCRPC patients with only lymph node metastases showed promising survival rates and excellent response to PSMA-RLT. [Extracted from the article]
Copyright of Cancer Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
New Findings in Prostate Cancer Described from Medical University of Vienna (Response To [<superscript>177</superscript>lu]Lu-psma Radioligand Therapy In Metastatic Castration-resistant Prostate Cancer Patients Presenting With Only Lymph Node Metastases).
|
---|---|
Zeitschrift: | Cancer Weekly, 2024-01-02, S. 639-639 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1071-7218 (print) |
Sonstiges: |
|